Gland Pharma Ltd.
Price
Daily candles · NSEWhat the numbers say
- Low return on equity: 3-year ROE 9.2%.
- Comfortable leverage: debt-to-equity of 0.02.
- Sales compounded at 21.1% over 3 years.
- Weak cash conversion (CFO/OP 0.60).
- Trades above its industry P/E (45.7 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- USFDA completes routine GMP inspection at Gland Pharma’s Visakhapatnam facility
The inspection was concluded with ZERO Form 483 Observations
- Gland Pharma reports 47% jump in Q1 consolidated net profit
The total consolidated income of the company has increased by 19.09% at Rs 1,861.50 crore for Q1FY27
- Gland Pharma executes strategic agreement with Global Pharmaceutical Company
The agreement is for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets
- Gland Pharma, Neuland Laboratories join forces for sterile API manufacturing
The company will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products
- Gland Pharma gets USFDA’s approval for Sugammadex Injection
According to IQVIA, the product had US sales of approximately $1.6 billion for the twelve months ending April 2026
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 6,431 | 5,617 | 5,665 | 3,625 | 4,401 |
| Other income | 316 | 214 | 170 | 240 | 224 |
| Total Income | 6,747 | 5,830 | 5,835 | 3,865 | 4,625 |
| Expenditure | 4,801 | 4,348 | 4,332 | 2,600 | 2,891 |
| Operating Profit | 1,946 | 1,483 | 1,503 | 1,265 | 1,734 |
| Interest | 33 | 42 | 26 | 7 | 5 |
| Depreciation | 424 | 378 | 345 | 147 | 110 |
| Profit before tax | 1,465 | 1,063 | 1,133 | 1,055 | 1,619 |
| Tax | 437 | 364 | 360 | 274 | 407 |
| Net Profit | 1,027 | 699 | 772 | 781 | 1,212 |
| EPS (₹) | 62.35 | 42.40 | 46.90 | 47.44 | 73.81 |
| Net margin % | 16.0 | 12.4 | 13.6 | 21.5 | 27.5 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 16 | 16 | 16 |
| Reserves | 10,296 | 9,134 | 8,706 | 7,941 | 7,128 |
| Net worth | 10,312 | 9,151 | 8,722 | 7,957 | 7,144 |
| Total sources | 10,688 | 9,445 | 9,043 | 7,964 | 7,164 |
| Net block | 4,492 | 4,147 | 3,947 | 1,571 | 1,502 |
| Capital work in progress | 342 | 151 | 238 | 177 | 191 |
| Investments | 87 | 92 | 781 | 129 | 443 |
| Inventory | 1,744 | 1,685 | 1,655 | 1,945 | 1,186 |
| Debtors | 1,891 | 1,517 | 1,559 | 871 | 1,075 |
| Cash & bank | 3,359 | 2,556 | 1,839 | 3,771 | 3,093 |
| Book value (₹) | 625.91 | 555.40 | 529.56 | 483.12 | 434.84 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 1,031 | 915 | 997 | 364 | 791 |
| From investing | 138 | 1,705 | -1,757 | 1,208 | -1,003 |
| From financing | -417 | -433 | -799 | 15 | 35 |
| Net change in cash | 752 | 2,186 | -1,560 | 1,587 | -177 |
| Free cash flow | 1,169 | 2,619 | -760 | 1,572 | -212 |
| Closing cash | 3,359 | 2,556 | 357 | 1,909 | 319 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 15.0 | 12.0 | 13.6 | 14.0 | 24.8 |
| ROE % | 10.6 | 7.8 | 9.3 | 10.3 | 18.6 |
| PAT margin % | 16.0 | 12.4 | 13.6 | 21.5 | 27.5 |
| EBIT margin % | 23.3 | 19.7 | 20.5 | 29.3 | 36.9 |
| Debt / equity | 0.02 | 0.03 | 0.04 | 0.00 | 0.00 |
| Current ratio | 4.68 | 4.33 | 4.04 | 9.46 | 10.05 |
| Interest cover | 45.01 | 26.30 | 44.23 | 142.61 | 309.77 |
| Sales growth % | 14.5 | -0.9 | 56.3 | -17.6 | 27.1 |
| Dividend per share (₹) | 20.00 | 18.00 | 20.00 | 0.00 | 0.00 |
| Payout % | 32.1 | 42.5 | 42.6 | 0.0 | 0.0 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Gland Pharma Ltd. (GLAND) last traded at ₹2,850.40 on the NSE, down +2.88% on the session. Prices on this page are indicative and for information only.
Gland Pharma Ltd. has traded between ₹1,573.60 and ₹3,171.00 over the last 52 weeks on the NSE.
Gland Pharma Ltd. has a market capitalisation of about ₹46,963 crore.
Gland Pharma Ltd. trades at a P/E of 45.7, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for GLAND from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Gland Pharma Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in